Publication:
New technologies - new insights into the pathogenesis of hepatic encephalopathy.

dc.contributor.authorBaker, Luisa
dc.contributor.authorLanz, Bernard
dc.contributor.authorAndreola, Fausto
dc.contributor.authorAmpuero, Javier
dc.contributor.authorWijeyesekera, Anisha
dc.contributor.authorHolmes, Elaine
dc.contributor.authorDeutz, Nicolaas
dc.date.accessioned2023-01-25T08:37:25Z
dc.date.available2023-01-25T08:37:25Z
dc.date.issued2016-09-30
dc.description.abstractHepatic encephalopathy (HE) is a neuropsychiatric syndrome which frequently accompanies acute or chronic liver disease. It is characterized by a variety of symptoms of different severity such as cognitive deficits and impaired motor functions. Currently, HE is seen as a consequence of a low grade cerebral oedema associated with the formation of cerebral oxidative stress and deranged cerebral oscillatory networks. However, the pathogenesis of HE is still incompletely understood as liver dysfunction triggers exceptionally complex metabolic derangements in the body which need to be investigated by appropriate technologies. This review summarizes technological approaches presented at the ISHEN conference 2014 in London which may help to gain new insights into the pathogenesis of HE. Dynamic in vivo 13C nuclear magnetic resonance spectroscopy was performed to analyse effects of chronic liver failure in rats on brain energy metabolism. By using a genomics approach, microRNA expression changes were identified in plasma of animals with acute liver failure which may be involved in interorgan interactions and which may serve as organ-specific biomarkers for tissue damage during acute liver failure. Genomics were also applied to analyse glutaminase gene polymorphisms in patients with liver cirrhosis indicating that haplotype-dependent glutaminase activity is an important pathogenic factor in HE. Metabonomics represents a promising approach to better understand HE, by capturing the systems level metabolic changes associated with disease in individuals, and enabling monitoring of metabolic phenotypes in real time, over a time course and in response to treatment, to better inform clinical decision making. Targeted fluxomics allow the determination of metabolic reaction rates thereby discriminating metabolite level changes in HE in terms of production, consumption and clearance.
dc.identifier.doi10.1007/s11011-016-9906-y
dc.identifier.essn1573-7365
dc.identifier.pmid27696270
dc.identifier.unpaywallURLhttp://discovery.ucl.ac.uk/1521939/1/Baker_New%20technologies%20new%20insights_Highlighting_removed_Combined.pdf
dc.identifier.urihttp://hdl.handle.net/10668/10499
dc.issue.number6
dc.journal.titleMetabolic brain disease
dc.journal.titleabbreviationMetab Brain Dis
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number1259-1267
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectGenomics
dc.subjectHepatic encephalopathy
dc.subjectMetabonomics
dc.subjectMicroRNA
dc.subjectNuclear magnetic resonance spectroscopy
dc.subjectTargeted fluxomics
dc.subject.meshAnimals
dc.subject.meshHepatic Encephalopathy
dc.subject.meshHumans
dc.subject.meshMagnetic Resonance Spectroscopy
dc.subject.meshMetabolomics
dc.subject.meshMicroRNAs
dc.titleNew technologies - new insights into the pathogenesis of hepatic encephalopathy.
dc.typeresearch article
dc.type.hasVersionSMUR
dc.volume.number31
dspace.entity.typePublication

Files